The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II study investigating cabozantinib in patients with refractory metastatic colorectal cancer (AGICC 17CRC01).
 
Aaron James Scott
Consulting or Advisory Role - Exelixis; Exelixis; Exelixis; Exelixis
Research Funding - Exelixis; Exelixis; Exelixis; Exelixis; Five Prime Therapeutics; Five Prime Therapeutics; Five Prime Therapeutics; Five Prime Therapeutics; Genentech; Genentech; Genentech; Genentech; Incyte; Incyte; Incyte; Incyte
Travel, Accommodations, Expenses - Exelixis; Exelixis; Exelixis; Exelixis
 
Steven J. Cohen
Consulting or Advisory Role - Bayer; Bayer; Bayer; Bayer; Exelixis; Exelixis; Exelixis; Exelixis
 
Atrayee Basu Mallick
Research Funding - Advenchen Laboratories (Inst); Advenchen Laboratories (Inst); Advenchen Laboratories (Inst); Advenchen Laboratories (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); The Academic GI Cancer Consortium (Inst); The Academic GI Cancer Consortium (Inst); The Academic GI Cancer Consortium (Inst); The Academic GI Cancer Consortium (Inst); TRACON Pharma (Inst); TRACON Pharma (Inst); TRACON Pharma (Inst); TRACON Pharma (Inst)
Travel, Accommodations, Expenses - Lilly; Lilly; Lilly; Lilly
 
Efrat Dotan
Honoraria - Boston Biomedical; Boston Biomedical; Boston Biomedical; Boston Biomedical; Pfizer; Pfizer; Pfizer; Pfizer
Consulting or Advisory Role - ARMO BioSciences; ARMO BioSciences; ARMO BioSciences; ARMO BioSciences; Boston Biomedical; Boston Biomedical; Boston Biomedical; Boston Biomedical
Research Funding - Bayer (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Boston Biomedical (Inst); Boston Biomedical (Inst); Boston Biomedical (Inst); Boston Biomedical (Inst); GlaxoSmithKline (Inst); GlaxoSmithKline (Inst); GlaxoSmithKline (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Incyte (Inst); Incyte (Inst); Incyte (Inst); MedImmune (Inst); MedImmune (Inst); MedImmune (Inst); MedImmune (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb
 
Philip Jordan Gold
No Relationships to Disclose
 
Howard S. Hochster
Consulting or Advisory Role - Amgen; Amgen; Amgen; Amgen; Bayer; Bayer; Bayer; Bayer; Exelixis; Exelixis; Exelixis; Exelixis; Genentech; Genentech; Genentech; Genentech
 
Somasundaram Subramaniam
Consulting or Advisory Role - Bayer; Bayer; Bayer; Bayer; Exelixis; Exelixis; Exelixis; Exelixis; Lexicon; Lexicon; Lexicon; Lexicon; Takeda; Takeda; Takeda; Takeda
Speakers' Bureau - Exelixis; Exelixis; Exelixis; Exelixis
 
Afsaneh Barzi
Consulting or Advisory Role - Bayer Technology System; Bayer Technology System; Bayer Technology System; Bayer Technology System; bioTheranostics; bioTheranostics; bioTheranostics; bioTheranostics; Merrion; Merrion; Merrion; Merrion
Research Funding - Bayer (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Merck (Inst)
 
Patrick Jud Blatchford
No Relationships to Disclose
 
Wells A. Messersmith
Consulting or Advisory Role - Five Prime Therapeutics (Inst); Five Prime Therapeutics (Inst); Five Prime Therapeutics (Inst); Five Prime Therapeutics (Inst); Gilead Sciences (Inst); Gilead Sciences (Inst); Gilead Sciences (Inst); Gilead Sciences (Inst); Purdue Pharma (Inst); Purdue Pharma (Inst); Purdue Pharma (Inst); Purdue Pharma (Inst); Tanabe Research (Inst); Tanabe Research (Inst); Tanabe Research (Inst); Tanabe Research (Inst)
Research Funding - Aduro Biotech (Inst); Aduro Biotech (Inst); Aduro Biotech (Inst); Aduro Biotech (Inst); Alexo Therapeutics (Inst); Alexo Therapeutics (Inst); Alexo Therapeutics (Inst); Alexo Therapeutics (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Beigene (Inst); Beigene (Inst); Beigene (Inst); Beigene (Inst); D3 (Inst); D3 (Inst); D3 (Inst); D3 (Inst); Immunomedics (Inst); Immunomedics (Inst); Immunomedics (Inst); Immunomedics (Inst); OncoMed (Inst); OncoMed (Inst); OncoMed (Inst); OncoMed (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Roche/Genentech (Inst); Roche/Genentech (Inst); Roche/Genentech (Inst); Roche/Genentech (Inst); Takeda (Inst); Takeda (Inst); Takeda (Inst); Takeda (Inst)